Ivosidenib
Tibsovo
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Accepting patients
CPX-351 Plus Ivosidenib
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS
Learn more- IDH1 Inhibitor
- Phase 2
Accepting patients
Ivosidenib (AG120)
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IDH1 Inhibitor
- Phase 1/2
- Has results
Accepting patients
Ivosidenib and Combination Chemotherapy
Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
Learn more- IDH1 Inhibitor
- MIDH2 Inhibitor
- White Blood Cell Stimulant
- Phase 1
Accepting patients
AG-120
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Learn more- IDH1 Inhibitor
- Phase 1